Pluristem Therapeutics Inc. (PSTI) announced the receipt of a joint grant awarded by the Israeli Ministry of Defense and the Israel Innovation Authority for the development of the company’s PLX cells for the treatment of burn injuries.
Source: www.rttnews.com
Pluristem Therapeutics Inc. received a joint grant from Israeli Ministry of Defense and the Israel Innovation Authority for the development its PLX cells for the treatment of burn injuries. Pluristem Therapeutics is engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. Pluristem will collaborate with the Israeli Defense Forces (IDF) medical corps and professionals who specialize in burn injuries from Israeli hospitals.
